Pancreatic cancer has one of the lowest survival rates for all cancers, but there are some people who achieve long-term survival. We are looking at those patients, with the goal of identifying what are some treatments and experiences that do work. Learning about treatment combinations and unique therapies that have led to success can open doors for where our research should be focused moving forward.

Do you have small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC)? Has your lung cancer come back or did not get better with the last treatment you were given? If so, you may be able to take part in a gene therapy research study that uses your own modified immune cells as treatment.

The purpose of this study is to find out if treatment with the study drug, Bexmarilimab, along with standard of care can help with your type of cancer.

This is a prospective study that will look for the kinetics of circulating tumor DNA (ctDNA) in patients with hematologic and pediatric cancer before and after undergoing standard of care treatment regimens where radiation therapy is a treatment.

The purpose of this study is to determine if MIRV plus Bev can help to prevent your cancer from returning or delaying your cancer's return.

Have you been diagnosed with relapsed or refractory multiple myeloma? If so, you may be able to take part in a research study looking at the safety of giving a new drug to patients with multiple myeloma.

Are you 16 years and older, have Eosinophilic Esophagitis, have tried other therapies but they have not worked, and you have had multiple dilations for narrowing in your throat in the past 12 months? If you meet these criteria then you may be eligible for a study investigating the use of dupilumab to treat EoE patients with severe strictures. Compensation provided.

Have you been diagnosed with triple negative breast cancer? If so, you may be able to take part in a research study looking at the safety of giving a new drug called Sacituzumab Govitecan with or without a drug called Pembrolizumab to patients with PDL-1-negative metastatic triple negative breast cancer.

The purpose of this study is to assess the physical activity practices of college-age Native American adults.

The purpose of this research study is to see if adding the PARP inhibitor olaparib concurrently with SRS followed by immunotherapy (durvalumab) and chemotherapy will lead to better control of breast cancer that has spread to the brain better than the standard approach.